Breaking News Instant updates and real-time market news.

BABA

Alibaba

$177.94

-1.21 (-0.68%)

, TWTR

Twitter

$38.47

-0.33 (-0.85%)

07:35
05/13/19
05/13
07:35
05/13/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in Alibaba (BABA), Twitter (TWTR), Snap Inc. (SNAP), Centene (CNC), Amarin (AMRN), Bausch Health (BHC), Pinterest (PINS), GoPro (GPRO), Encana (ECA), and BlackBerry (BB).

BABA

Alibaba

$177.94

-1.21 (-0.68%)

TWTR

Twitter

$38.47

-0.33 (-0.85%)

SNAP

Snap

$10.49

-0.5 (-4.55%)

CNC

Centene

$55.07

0.34 (0.62%)

AMRN

Amarin

$17.32

(0.00%)

BHC

Bausch Health

$25.30

-0.785 (-3.01%)

PINS

Pinterest

$29.05

0.25 (0.87%)

GPRO

GoPro

$6.42

-0.245 (-3.68%)

ECA

Encana

$6.60

-0.115 (-1.71%)

BB

BlackBerry

$8.82

-0.025 (-0.28%)

  • 15

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 20

    May

  • 29

    May

  • 04

    Jun

  • 23

    Jul

BABA Alibaba
$177.94

-1.21 (-0.68%)

05/07/19
KEYB
05/07/19
NO CHANGE
Target $240
KEYB
Overweight
Alibaba price target raised to $240 from $210 at KeyBanc
KeyBanc analyst Hans Chung raised his price target for Alibaba to $240 from $210, saying he still sees a meaningful upside to the stock despite a 37% rally year to date, as he believes the company will continue to be a dominant leader and pioneer in e-com 3.0. In the near to mid-term, the analyst expects feed monetization to start in the near future and contribute a meaningful growth. Freshippo's margin could be improved, driven by more stores ramped and matured, he adds. Chung reiterates an Overweight rating on the shares.
05/13/19
THCP
05/13/19
NO CHANGE
Target $220
THCP
Buy
Alibaba price target raised to $220 from $180 at TH Data Capital
TH Data Capital analyst Tian Hou raised his price target for Alibaba Group to $220 from $180 and maintains a Buy rating on the shares ahead of the company's fiscal Q4 results on May 15. Alibaba's Q4 revenue growth is likely to be better than consensus given its continuing innovations in the marketplace, Hou tells investors in a pre-earnings research note. "Non-stop adoption of innovations in the marketplace keeps the existing business energetic," says the analyst.
04/15/19
LEHM
04/15/19
NO CHANGE
Target $220
LEHM
Overweight
Alibaba price target raised to $220 from $200 at Barclays
Barclays analyst Gregory Zhao raised his price target for Alibaba Group Holding to $220 from $200 ahead of the company's Q4 results and keeps an Overweight rating on the shares. China's macro environment is recovering from the trough in Q4 and will stabilize, "thanks to the incentive measures and tax cut by government," Zhao tells investors in a pre-earnings research note.
05/07/19
MZHO
05/07/19
UPGRADE
Target $55
MZHO
Buy
Mizuho upgrades Ctrip to Buy with $55 price target into Q1 results
Mizuho analyst James Lee last night upgraded Ctrip (CTRP) to Buy from Neutral and raised his price target for the shares to $55 from $35 ahead of the company's Q1 results. The analyst expects decreased competition along with an improved macro environment and yuan appreciation will drive both domestic and outbound travel. As such, he raised his three-year annual EBITDA growth estimate for Ctrip to 35% from 23% on improved long-term fundamentals. Alibaba (BABA) remains Lee's top pick in the China Internet space.
TWTR Twitter
$38.47

-0.33 (-0.85%)

04/30/19
JMPS
04/30/19
NO CHANGE
Target $1300
JMPS
Outperform
Alphabet price target lowered to $1,300 from $1,375 at JMP Securities
JMP Securities analyst Ronald Josey said competition "may have played a role" in Alphabet's (GOOGL) worse than expected Q1 revenue given that better than expected advertising results have recently been reported by Facebook (FB), Twitter (TWTR), Snap (SNAP) and Amazon (AMZN). However, he believes the "majority of the deceleration was self-imposed," he tells investors in a post-earnings research note. Some of the company's product changes, such as changes at YouTube's recommendation engine, likely acted as a headwind, the analyst surmised. Josey sees benefits from investments in hardware and Google Cloud and thinks that multiple monetization opportunities remain for Alphabet, leading him to maintain an Outperform rating on the stock, though he lowered his price target on shares to $1,300 from $1,375.
04/24/19
JEFF
04/24/19
NO CHANGE
Target $41
JEFF
Hold
Twitter price target raised to $41 from $33 at Jefferies
Jefferies analyst Brent Thill raised his price target for Hold-rated Twitter to $41 from $33 saying the company yesterday "surprised to the upside" on daily active users. The analyst, however, still sees work to be done to fix Twitter's underlying platform for advertisers and users. He's encouraged by the company's better monetization, but worries that with the stock up 38% year-to-date, it is outperforming fundamental drivers.
04/24/19
GUGG
04/24/19
NO CHANGE
Target $44
GUGG
Buy
Twitter price target raised to $44 from $41 at Guggenheim
Guggenheim analyst Michael Morris said Twitter's progress on improving its platform health is creating a more relevant, conversational experience for users and delivering a unique platform for advertisers. He expects this momentum to continue through 2019, with Twitter further growing its share of global advertising budgets, and raise his price target on the shares to $44 from $41 following the company's Q1 report. Morris maintains a Buy rating on Twitter shares.
04/24/19
RHCO
04/24/19
NO CHANGE
Target $36
RHCO
Hold
Twitter price target raised to $36 from $34 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Twitter to $36, saying the company's Q1 results showed "improving health" of its platform for users and advertisers while driving "stronger" profitability and user metrics. The analyst notes that the company's newer products, advertising formats like video, and improved "abuse" detection have resonated with both groups. Squali is keeping his Hold rating on Twitter however because of the "fair valuation" on the stock, higher growth in expenditures relative to revenues expected in 2019, and tougher comps for the back half of the year.
SNAP Snap
$10.49

-0.5 (-4.55%)

04/24/19
JEFF
04/24/19
NO CHANGE
Target $13
JEFF
Hold
Snap shares already reflect Q1 improvements, says Jefferies
Jefferies analyst Brent Thill raised his price target for Snap to $13 from $11 but keeps a Hold rating on the shares following the company's Q1 results. Snap returned to user growth while also driving an acceleration of average revenue per user growth, Thill tells investors in a post-earnings research note. The analyst likes the trajectory of the business but believes the stock "already reflects these improvements."
04/24/19
04/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/24/19
RHCO
04/24/19
NO CHANGE
Target $11
RHCO
Hold
Snap price target raised to $11 from $8 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Snap to $11 after its "better than expected" Q1 results with a beat on revenue and earnings, positive user trends, and above-consensus guidance for Q2. The analyst cites increasing advertiser adoption and greater reach into key demographic but keeps his Hold rating on the stock, stating that the company still has "much left to do on product execution, monetization, user growth, and sustained cost containment to achieve profitability."
CNC Centene
$55.07

0.34 (0.62%)

05/10/19
SBSH
05/10/19
UPGRADE
SBSH
Buy
Centene upgraded to Buy from Neutral at Citi
Citi analyst Ralph Giacobbe upgraded Centene to Buy from Neutral.
05/10/19
05/10/19
UPGRADE

Citi upgrades Anthem, Centene, UnitedHealth to Buy after 'extreme' selloff
Citi analyst Ralph Giacobbe upgraded Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) to Buy from Neutral while maintaining Buy ratings on Cigna (CI) and Humana (HUM). The magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone," Giacobbe tells investors in a research note. The analyst sees favorable risk/rewards in the sector and does not subscribe to the view of a continued "overhang" and "uncertainty." Instead, Giacobbe expects a share recovery as "more realistic views prevail and investors become more numb to the low-likelihood headlines and political rhetoric of single payor."
05/07/19
SBSH
05/07/19
NO CHANGE
SBSH
Citi sees low likelihood of Centene walking from WellCare deal
Amid reports suggesting shareholders could challenge Centene's (CNC) acquisition of WellCare (WCG), and Humana (HUM) possibly being interested in a takeover of Centene if the WellCare deal was dropped, Citi analyst Ralph Giacobbe says he's be surprised to see the deal unravel. Further, he'd be equally surprised to see Humana come over the top for Centene after its Medicaid win in Florida and recent commentary citing optimism in its organic direction. That said, there is a scarcity of Medicaid assets, and Humana has discussed its interest in dual and other higher acuity Medicaid populations, Giacobbe tells investors in a research note. Nonetheless, the analyst ultimately sees a low likelihood of Centene walking from the WellCare deal.
05/10/19
05/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. 3D Systems (DDD) upgraded to Neutral from Underweight at JPMorgan with analyst Paul Coster noting the stock is down 25% this week after posting "lackluster" Q1 results. 2. Jones Lang LaSalle (JLL) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying the company's earnings declined in Q1 due to tough comps, but this should reverse quickly. 3. Ford (F) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy stating the company's earnings are starting to hit a "sustainable inflection" due to favorable product cadence in the North America market and its restructuring efforts. 4. Whirlpool (WHR) upgraded to Buy from Neutral at Longbow with analyst David MacGregor seeing earnings upside from better than expected North American margin performance, a "gradually improving" environment in the EMEA and a favorable cyclical turn in Latin America. 5. Anthem (ANTM), Centene (CNC), and UnitedHealth (UNH) upgraded to Buy from Neutral at Citi with analyst Ralph Giacobbe the magnitude of the selloff in managed care stocks on fears of Medicare for All has been "extreme and overdone". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMRN Amarin
$17.32

(0.00%)

04/24/19
JEFF
04/24/19
NO CHANGE
Target $30
JEFF
Buy
Jefferies sees potential beat for Amarin on growing Q1 Vascepa sales
Jefferies analyst Michael Yee says that despite Amarin's management cautioning to expect seasonality in Q1, scripts are up over 16% quarter over quarter, appearing to track to $75M-$80M in Q1 versus consensus of $67M and Jefferies at $79M. Historically, Vascepa sales have declined in Q1 over the past couple of years, but the analyst sees an increase this year instead due to major new CVOT data during Q4 now published in the NEJM, huge salesforce increase to 400 from 150 recently, and positive doctor channel checks suggesting reimbursement has not been much issue. Yee believes 2019 guidance of $350M appears conservative. He reiterates a Buy rating and $30 price target on the shares.
03/28/19
STFL
03/28/19
NO CHANGE
STFL
Buy
ADA endorsement a 'big score' for Amarin's Vascepa, says Stifel
After the American Diabetes Association updated its Standards of Medical Care to include a recommendation that Vascepa be considered for certain patients with diabetes, Stifel analyst Derek Archila called the news a "big score" for Vascepa and a significant endorsement of Vascepa's REDUCE-IT data. The analyst, who continues to view Amarin's 2019 Vascepa sales guidance as beatable, keeps a Buy rating on Amarin shares.
05/02/19
SBSH
05/02/19
NO CHANGE
Target $23
SBSH
Buy
Amarin selloff creates attractive entry point, says Citi
Citi analyst Joel Beatty believes the selloff yesterday in shares of Amarin (AMRN) brings an attractive entry point. He raised his price target for the stock to $23 from $20 and keeps a Buy rating on the name. The analyst sees five potential upside catalysts this year, including a likely supportive ICER cost-effectiveness review and potential priority review from the FDA. Further, while an acquisition of Amarin is possible, the company acquiring The Medicines Co. (MDCO) or Esperion (ESPR) "could also be a viable path," says Beatty.
04/29/19
JEFF
04/29/19
NO CHANGE
Target $30
JEFF
Buy
Amarin settlement could be 'key catalyst' for shares, says Jefferies
Recent updates in the dosing patent litigation between Amarin (AMRN) and Hikma and Reddy's show the sides have been progressing and both cases were moved under the same judge in Nevada, Jefferies analyst Michael Yee tells investors in a research note. The analyst believes uncertainty around the ongoing litigation presents a risk for investors and that there is a perception on the Street that the cases impactsany potential acquisition transaction for Amarin until there is clarity. With Judge Du setting a trial date for January 13, 2020, at least a timeline for one of the two major cases is known, Yee writes. He believes a potential "key catalyst" could be a settlement beforehand. The analyst continues to think another settlement, like the one Amarin reached with Teva (TEVA), and removal of the overhang is "likely in time and is a win-win for all parties." This "could be quite important" for Amarin shares, says Yee. He keeps a Buy rating on Amarin with a $30 price target.
BHC Bausch Health
$25.30

-0.785 (-3.01%)

05/13/19
JPMS
05/13/19
UPGRADE
Target $28
JPMS
Neutral
JPMorgan upgrades Bausch Health to Neutral on 'stabilizing' EBITDA
JPMorgan analyst Chris Schott upgraded Bausch Health to Neutral from Underweight and raised his price target for the shares to $28 from $25. While a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here," Schott tells investors in a research note. The analyst's sum-of-the-parts valuation suggests little downside for Bausch Health shares.
05/13/19
JPMS
05/13/19
UPGRADE
JPMS
Neutral
Bausch Health upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Christopher Schott upgraded Bausch Health to Neutral from Underweight.
05/07/19
MZHO
05/07/19
NO CHANGE
Target $45
MZHO
Buy
Bausch Health price target raised to $45 from $41 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Bausch Health Companies to $45 from $41 citing yesterday's "beat and raise" quarter. The analyst reiterates a Buy rating on the shares.
04/26/19
JEFF
04/26/19
NO CHANGE
Target $31
JEFF
Buy
Bausch Health approval could help reaccelerate revenue, says Jefferies
Bausch Health yesterday "finally" received approval for its topical combination plaque psoriasis drug Duobrii after a protracted FDA review, Jefferies analyst David Steinberg tells investors in a research note. The analyst points out that Duobrii is the last of Bausch's "Significant 7" products to be approved from the company's late-stage dermatology pipeline. He forecasts Duobrii sales of $150M and believes the launch could help reaccelerate revenue for the company's Ortho Dermatology division post a series of loss of exclusivities. Steinberg keeps a Buy rating on Bausch Health with a $31 price target.
PINS Pinterest
$29.05

0.25 (0.87%)

05/13/19
FBCO
05/13/19
INITIATION
Target $28
FBCO
Neutral
Pinterest initiated with a Neutral at Credit Suisse
Credit Suisse analyst Stephen Ju started coverage of Pinterest with a Neutral rating and a $28 price target. The analyst notes that stock outperformance from current levels depends on speed of international ramp.
05/13/19
UBSW
05/13/19
INITIATION
Target $31
UBSW
Neutral
Pinterest initiated with a Neutral at UBS
UBS analyst Eric Sheridan initiated Pinterest with a Neutral rating and a price target of $31. The analyst is positive on the company's user growth potential, opportunity with an under-monetized international base, and its position amid the "secular tailwinds of the offline to online advertising shift." Sheridan also points to the 20% post-IPO rally in Pinterest stock price and sees its valuation as fair.
05/13/19
LEHM
05/13/19
INITIATION
Target $28
LEHM
Equal Weight
Pinterest initiated with an Equal Weight at Barclays
Barclays analyst Ross Sandler started Pinterest with an Equal Weight rating and $28 price target. The analyst says the company's current revenue multiple, along with the track record of mobile advertising initial public offerings "chopping around for a bit after the initial post IPO pop," gives him pause in the stock.
05/13/19
BOFA
05/13/19
INITIATION
Target $32
BOFA
Neutral
Pinterest initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Justin Post initiated Pinterest with a Neutral and $32 price target citing valuation premium and does not expects any "massive" upside surprises in 2019.
GPRO GoPro
$6.42

-0.245 (-3.68%)

02/07/19
JPMS
02/07/19
NO CHANGE
Target $7.5
JPMS
Neutral
GoPro target raised to $7.50 on 'solid' Q4 results at JPMorgan
JPMorgan analyst Paul Coster raised his price target for GoPro to $7.50 from $7 citing the company's "solid" Q4 results. The company delivered on a promised return to growth and profitability in the quarter, with prospects for a better 2019 now that it has concluded the cost-reduction program, Coster tells investors in a post-earnings research note. "This feels like a turning point toward better financial performance," says the analyst. However, despite being "e incrementally constructive," Coster remains on the sidelines with a Neutral rating "given the tough road back to consistent profitability."
02/07/19
LBOW
02/07/19
NO CHANGE
LBOW
Neutral
GoPro underlying demand still looks challenged, says Longbow
Longbow analyst Nikolay Todorov said GoPro management "appears to have stabilized the ship and put the company back on the path to profitability," noting that the company's 2019 guidance suggests a return to sustainable top-line growth. However, it looks to him like growth in 2019 will be mostly driven by average selling price increases, while units "will grow only modestly at best." Given his concerns about underlying demands, and his lack of conviction in ASP growth beyond 2019, Todorov keeps a Neutral rating on GoPro shares.
05/10/19
JPMS
05/10/19
NO CHANGE
Target $8
JPMS
Neutral
JPMorgan says GoPro execution improving, boosts target to $8
JPMorgan analyst Paul Coster says GoPro's execution is improving with the company now a year into consistently meeting expectations, expanding gross margins and returning to sustainable profitability on a narrower product line-up. The analyst raised his price target for GoPro to $8 from $7.50 following the company's Q1 results but keeps a Neutral rating on the name. GoPro's growth "remains elusive," says Coster.
04/09/19
LBOW
04/09/19
NO CHANGE
LBOW
Neutral
GoPro checks point to results tracking towards guidance high-end, says Longbow
Longbow analyst Nikolay Todorov raised his first half sales and EPS forecasts for GoPro, stating that online indicators and his channel checks suggest that the company's camera mix is skewing towards HERO7 Black more than he expected. He believes revenue and EPS are tracking towards the high-end of GoPro's first half guidance, at least, and views consensus for 2Q sales and EPS as too low, Todorov tells investors. However, he keeps a Neutral rating on the stock, citing questions that remain regarding unit growth and a shrinking market over time.
ECA Encana
$6.60

-0.115 (-1.71%)

05/01/19
05/01/19
DOWNGRADE

Market Perform
Encana downgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst Bob Brackett downgraded Encana to Market Perform from Outperform after the company reported quarterly results, and as he sees relatively fewer catalysts for remainder of 2019. Further, in terms of share buybacks, the analyst notes that at 60% complete have failed to re-rate the stock.
04/30/19
BERN
04/30/19
DOWNGRADE
BERN
Market Perform
Encana downgraded to Market Perform from Outperform at Bernstein
04/29/19
JPMS
04/29/19
DOWNGRADE
Target $12
JPMS
Neutral
Encana resumed with a Neutral from Overweight at JPMorgan
JPMorgan analyst Arun Jayaram resumed coverage of Encana and downgraded the shares to Neutral from Overweight with a $12 price target. The analyst has a "positive" bias on the shares, but he wants to wait for additional drilling results from the company's acquired NFX STACK acreage before revisiting his Neutral thesis.
04/12/19
GSCO
04/12/19
NO CHANGE
GSCO
Goldman downgrades California Resources, Chesapeake to Sell, upgrades Murphy
Within the Exploration and Production space, Goldman Sachs analyst Brian Singer recommends selling stocks where the valuation post recent rallies "appears at odds" with the company's competitive positioning. With that in mind, Singer downgraded both California Resources (CRC) and Chesapeake Energy (CHK) to Sell from Neutral. California Resources has a low decline rate and competitive supply cost but unfavorable debt cost that does not warrant the extent of its current valuation premium, says the analyst. For Chesapeake, Singer sees less favorable supply cost and corporate returns. The analyst also upgraded Murphy Oil (MUR) to Neutral from Sell. He believes the stock's current valuation appears more in line with its competitive positioning. Singer recommends buying "low cost oil suppliers" Encana (ECA), Parsley Energy (PE), Pioneer Natural (PXD) and EOG Resources (EOG) and Chevron (CVX).
BB BlackBerry
$8.82

-0.025 (-0.28%)

01/29/19
ADAM
01/29/19
NO CHANGE
Target $9
ADAM
Hold
BlackBerry meetings reinforce long-term growth potential, says Canaccord
Canaccord analyst T. Michael Walkley met with BlackBerry management and came away confident in his belief the company is tracking toward his longer-term targets driven by its QNX opportunity, synergy potential from the Cylance acquisition, execution on its Spark platform rollout, and licensing growth potential. Walkley maintained his Hold rating and $9 price target on BlackBerry shares.
03/22/19
MSCO
03/22/19
INITIATION
Target $10
MSCO
Equal Weight
BlackBerry resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst James Faucette resumed coverage of BlackBerry with an Equal Weight rating and $10 price target, stating that he believes Cylance should accelerate software growth, but that will take time. The key to being more positive on BlackBerry is still its opportunity in the BlackBerry Technology Solutions, or automotive, business, contends Faucette.
12/24/18
12/24/18
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. CarMax (KMX) upgraded to Buy from Neutral at Guggenheim with analyst Ali Faghri citing valuation. 2. Newtek Business (NEWT) upgraded to Outperform from Market Perform at Raymond James. 3. RPM (RPM) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. BlackBerry (BB) downgraded to Sell from Buy at Veritas. 5. Histogenics (HSGX) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth saying the FDA is requiring an additional study with NeoCart. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
BOFA
04/05/19
NO CHANGE
Target $8.5
BOFA
Underperform
BlackBerry stock can't hold strength, says BofA/Merrill
BofA/Merrill analyst Daniel Bartus reiterated an Underperform rating and $8.50 price target on BlackBerry, telling investors in a research note that he has several reasons to remain cautious. Of note, Bartus says that while BlackBerry has beaten Street expectations in each of the last seven quarters, the stock has declined 6% since its first quarter results in June 2017. Additionally, Bartus sees "tough" comps for IP Licensing, the main area of outperformance, going forward, and says its Enterprise segment, its "most important" segment, is also the weakest segment.

TODAY'S FREE FLY STORIES

TACO

Del Taco

$10.90

-0.13 (-1.18%)

11:49
08/20/19
08/20
11:49
08/20/19
11:49
Periodicals
Del Taco said to hire bankers to consider sale, blog report claims »

Del Taco Restaurants has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 04

    Nov

FB

Facebook

$184.89

-1.33 (-0.71%)

11:44
08/20/19
08/20
11:44
08/20/19
11:44
Periodicals
Executive says Facebook new privacy feature may dent revenue, Bloomberg reports »

Facebook finished a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

M

Macy's

$15.70

-0.43 (-2.67%)

11:40
08/20/19
08/20
11:40
08/20/19
11:40
Options
Short-term put buyer as Macy's hits new lows »

Short-term put buyer as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MA

MasterCard

$279.09

1.05 (0.38%)

, GS

Goldman Sachs

$201.86

-0.35 (-0.17%)

11:34
08/20/19
08/20
11:34
08/20/19
11:34
Hot Stocks
Apple launches Apple Card for U.S. customers »

Apple Card, a credit card…

MA

MasterCard

$279.09

1.05 (0.38%)

GS

Goldman Sachs

$201.86

-0.35 (-0.17%)

UBER

Uber

$35.81

1.23 (3.56%)

AAPL

Apple

$212.98

2.66 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 27

    Oct

BYND

Beyond Meat

$155.67

11.23 (7.77%)

, HAIN

Hain Celestial

$19.80

-2.08 (-9.51%)

11:31
08/20/19
08/20
11:31
08/20/19
11:31
On The Fly
Beyond Meat upgrade, HP downgrade among today's top analyst actions »

Check out today's top…

BYND

Beyond Meat

$155.67

11.23 (7.77%)

HAIN

Hain Celestial

$19.80

-2.08 (-9.51%)

HPQ

HP Inc.

$19.06

-0.16 (-0.83%)

ABBV

AbbVie

$67.39

0.84 (1.26%)

PPC

Pilgrim's Pride

$30.60

1.45 (4.97%)

SQ

Square

$64.52

0.41 (0.64%)

PYPL

PayPal

$108.44

0.8 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 09

    Sep

  • 10

    Sep

  • 15

    Sep

  • 16

    Sep

  • 25

    Sep

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

HGV

Hilton Grand Vacations

$31.11

2.905 (10.30%)

, APO

Apollo Global

$34.24

0.55 (1.63%)

11:29
08/20/19
08/20
11:29
08/20/19
11:29
Recommendations
Hilton Grand Vacations, Apollo Global, Blackstone analyst commentary at Goldman Sachs »

Potential consolidation…

HGV

Hilton Grand Vacations

$31.11

2.905 (10.30%)

APO

Apollo Global

$34.24

0.55 (1.63%)

BX

Blackstone

$48.70

0.85 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AAPL

Apple

$213.03

2.71 (1.29%)

11:29
08/20/19
08/20
11:29
08/20/19
11:29
Periodicals
Apple's health team sees departures as tension brews over direction, CNBC says »

Apple's health team…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLEX

Flex

$10.05

0.02 (0.20%)

11:25
08/20/19
08/20
11:25
08/20/19
11:25
Conference/Events
Flex to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

SIG

Signet Jewelers

$11.88

-0.45 (-3.65%)

11:20
08/20/19
08/20
11:20
08/20/19
11:20
Options
Put seller smacks bid for 2K Jan 10 puts in Signet Jewelers »

Put seller smacks bid for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

11:20
08/20/19
08/20
11:20
08/20/19
11:20
General news
Treasury announced $95 B in 4- and 8-week bills for Thursday »

Treasury announced $95 B…

TJX

TJX

$50.31

-1.24 (-2.41%)

11:19
08/20/19
08/20
11:19
08/20/19
11:19
Earnings
Breaking Earnings news story on TJX 

TJX sees Q4 EPS 74c-77c

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TJX

TJX

$50.32

-1.23 (-2.39%)

11:19
08/20/19
08/20
11:19
08/20/19
11:19
Earnings
TJX sees FY20 revenue $40.9B-$41.2B, consensus $41.33B »

Sees FY20 Marmaxx comp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TJX

TJX

$50.30

-1.25 (-2.42%)

11:18
08/20/19
08/20
11:18
08/20/19
11:18
Earnings
Breaking Earnings news story on TJX »

TJX sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TRMD

TORM A/S

$7.10

(0.00%)

11:17
08/20/19
08/20
11:17
08/20/19
11:17
Hot Stocks
Breaking Hot Stocks news story on TORM A/S »

TORM PLC (Class A Stock)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
08/20/19
08/20
11:17
08/20/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$50.16

-1.39 (-2.70%)

11:17
08/20/19
08/20
11:17
08/20/19
11:17
Earnings
Breaking Earnings news story on TJX »

TJX sees Marshall's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TJX

TJX

$50.16

-1.395 (-2.71%)

11:16
08/20/19
08/20
11:16
08/20/19
11:16
Hot Stocks
TJX sees buying back approximately $1.75B of TJX stock for FY20 »

Comments taken from Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
08/20/19
08/20
11:16
08/20/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VUZI

Vuzix

$1.88

-0.08 (-4.08%)

11:15
08/20/19
08/20
11:15
08/20/19
11:15
Hot Stocks
Vuzix receives follow-on Smart Glasses order from 1Minuut Innovation »

Vuzix Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$50.15

-1.4 (-2.72%)

11:14
08/20/19
08/20
11:14
08/20/19
11:14
Hot Stocks
Breaking Hot Stocks news story on TJX »

TJX saw small impact due…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TJX

TJX

$50.15

-1.4 (-2.72%)

11:13
08/20/19
08/20
11:13
08/20/19
11:13
Hot Stocks
Breaking Hot Stocks news story on TJX »

TJX CEO says feels…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

TRMD

TORM A/S

$7.10

(0.00%)

11:12
08/20/19
08/20
11:12
08/20/19
11:12
Hot Stocks
Breaking Hot Stocks news story on TORM A/S »

TORM PLC (Class A Stock)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZUO

Zuora

$13.60

-0.065 (-0.48%)

11:08
08/20/19
08/20
11:08
08/20/19
11:08
Earnings
Zuora appoints new Chief Product Officer, Chief Customer Officer »

Zuora (ZUO) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 10

    Sep

FB

Facebook

$184.95

-1.27 (-0.68%)

11:08
08/20/19
08/20
11:08
08/20/19
11:08
Hot Stocks
Facebook announces new tool for users' data control »

Facebook announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

11:08
08/20/19
08/20
11:08
08/20/19
11:08
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.